The Board restored the 30 percent rating for pansinusitis, effective September 19, 2023. The claim for a higher rating for bronchial asthma was denied.

The deciding factor: The evidence did not show that the Veteran's pansinusitis had improved to the extent necessary to warrant a reduction in rating, and his symptoms were mild and managed with over-the-counter medication. For bronchial asthma, there was no evidence of the required symptomatology for higher ratings.

Claimed conditions

pansinusitis, bronchial asthma

How they argued it

Direct service connection

Exposure basis

None

Rating assigned

None in this decision

Decision date

February 25, 2025

Citation

A25017019

Want to see how appeals like this one tend to go? Appeals like mine